Here are four notes:
1. The company named its cell therapy candidate for treating protruding and bulging lumbar disc disease, BRTX-100.
2. BRTX-100 is an autologous hypoxic cultured mesenchymal stem cell product.
3. The company will file an investigational new drug application with the FDA.
4. BioRestorative Therapies hopes to begin clinical trials for BRTX-100 this year.
More articles on spine:
13 statistics on neurosurgeon salary in 2016
5 notes on AANS’ new executive director Kathleen Craig
St. Rita’s Medical Center names Dr. Selvon St. Clair spine surgery director: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
